Optimal timing for prediction of pathologic complete response to neoadjuvant chemoradiotherapy with diffusion-weighted MRI in patients with esophageal cancer

[1]  K. Bradley,et al.  Temporal validation of metabolic nodal response of esophageal cancer to neoadjuvant chemotherapy as an independent predictor of unresectable disease, survival, and recurrence , 2019, European Radiology.

[2]  Xiance Jin,et al.  Prediction of response after chemoradiation for esophageal cancer using a combination of dosimetry and CT radiomics , 2019, European Radiology.

[3]  J. Yu,et al.  Predictive value of diffusion-weighted MR imaging in early response to chemoradiotherapy of esophageal cancer: a meta-analysis. , 2018, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[4]  T. Ruhstaller,et al.  Recurrence Patterns and Long-term Results After Induction Chemotherapy, Chemoradiotherapy, and Curative Surgery in Patients With Locally Advanced Esophageal Cancer , 2017, Annals of surgery.

[5]  Deif.  F-FDG-PET/CT in Esophageal Cancer , 2019 .

[6]  Derya Yakar,et al.  Preoperative image-guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (PRIDE): a multicenter observational study , 2018, BMC Cancer.

[7]  Zheng Zhang,et al.  Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial. , 2018, Radiology.

[8]  R. van Hillegersberg,et al.  Management of resectable esophageal and gastric (mixed adeno)neuroendocrine carcinoma: A nationwide cohort study. , 2018, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[9]  J. Lagendijk,et al.  Quantification of variations in intra-fraction motion of esophageal tumors over the course of neoadjuvant chemoradiotherapy based on cine-MRI , 2018, Physics in Medicine and Biology.

[10]  O. Mawlawi,et al.  Multimodal Imaging of Pathologic Response to Chemoradiation in Esophageal Cancer. , 2018, International journal of radiation oncology, biology, physics.

[11]  J. Lagendijk,et al.  DW-MRI and DCE-MRI are of complementary value in predicting pathologic response to neoadjuvant chemoradiotherapy for esophageal cancer , 2018, Acta oncologica.

[12]  J. Lagendijk,et al.  PO-0951: What CTV-to-PTV margins are required for esophageal cancer radiotherapy? , 2018 .

[13]  R. van Hillegersberg,et al.  Patient perspectives on repeated MRI and PET/CT examinations during neoadjuvant treatment of esophageal cancer. , 2018, The British journal of radiology.

[14]  H. Liu,et al.  Prediction of pathologic responders to neoadjuvant chemoradiotherapy by diffusion-weighted magnetic resonance imaging in locally advanced esophageal squamous cell carcinoma: a prospective study. , 2018, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[15]  J. Lagendijk,et al.  Correlation between functional imaging markers derived from diffusion-weighted MRI and 18F-FDG PET/CT in esophageal cancer , 2018, Nuclear medicine communications.

[16]  R. Valkema,et al.  Active surveillance in clinically complete responders after neoadjuvant chemoradiotherapy for esophageal or junctional cancer. , 2017, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[17]  M. V. van Oijen,et al.  Treatment strategies in recurrent esophageal or junctional cancer. , 2017, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[18]  T. Chenevert,et al.  Diffusion MRI in early cancer therapeutic response assessment , 2017, NMR in biomedicine.

[19]  B. Musall.  Quantitative DWI as an Early Imaging Biomarker of the Response to Chemoradiation in Esophageal Cancer , 2017 .

[20]  R. van Hillegersberg,et al.  Early outcomes from the Dutch Upper Gastrointestinal Cancer Audit , 2016, The British journal of surgery.

[21]  A. Schandl,et al.  Health-related quality of life 10 years after oesophageal cancer surgery. , 2016, European journal of cancer.

[22]  Chun Han,et al.  The diffusion-weighted magnetic resonance imaging (DWI) predicts the early response of esophageal squamous cell carcinoma to concurrent chemoradiotherapy. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[23]  J. Lagendijk,et al.  Dynamic contrast-enhanced MRI for treatment response assessment in patients with oesophageal cancer receiving neoadjuvant chemoradiotherapy. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[24]  M. Los,et al.  Diffusion-weighted MRI for Early Prediction of Treatment Response on Preoperative Chemoradiotherapy for Patients With Locally Advanced Rectal Cancer: A Feasibility Study , 2016, Annals of surgery.

[25]  K. Haustermans,et al.  Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  F. Giganti,et al.  Prognostic utility of diffusion-weighted MRI in oesophageal cancer: is apparent diffusion coefficient a potential marker of tumour aggressiveness? , 2016, La radiologia medica.

[27]  Stef van Buuren,et al.  Multivariate Imputation by Chained Equations , 2015 .

[28]  E. Steyerberg,et al.  Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. , 2015, The Lancet. Oncology.

[29]  J. Lagendijk,et al.  Diffusion-weighted magnetic resonance imaging for the prediction of pathologic response to neoadjuvant chemoradiotherapy in esophageal cancer. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[30]  U. Knigge,et al.  Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review , 2015, Diagnostics.

[31]  J. Reynolds,et al.  New-onset Atrial Fibrillation Post-surgery for Esophageal and Junctional Cancer: Incidence, Management, and Impact on Short- and Long-term Outcomes , 2014, Annals of surgery.

[32]  R. Berendsen,et al.  Interobserver Reproducibility of Diffusion-Weighted MRI in Monitoring Tumor Response to Neoadjuvant Therapy in Esophageal Cancer , 2014, PloS one.

[33]  Chun Han,et al.  Investigation of Using Diffusion-Weighted Magnetic Resonance Imaging to Evaluate the Therapeutic Effect of Esophageal Carcinoma Treatment , 2014, Oncology Research and Treatment.

[34]  M. Moerland,et al.  Quantification of esophageal tumor motion on cine-magnetic resonance imaging. , 2014, International journal of radiation oncology, biology, physics.

[35]  A. Kosinski,et al.  Predictors of anastomotic leak after esophagectomy: an analysis of the society of thoracic surgeons general thoracic database. , 2013, The Annals of thoracic surgery.

[36]  K. Haustermans,et al.  Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  H. Matsubara,et al.  Diffusion-Weighted Magnetic Resonance Imaging for Predicting and Detecting the Early Response to Chemoradiotherapy of Advanced Esophageal Squamous Cell Carcinoma , 2013, Digestive Surgery.

[38]  F. Giganti,et al.  Apparent diffusion coefficient modifications in assessing gastro-oesophageal cancer response to neoadjuvant treatment: comparison with tumour regression grade at histology , 2013, European Radiology.

[39]  E W Steyerberg,et al.  Preoperative chemoradiotherapy for esophageal or junctional cancer. , 2012, The New England journal of medicine.

[40]  Karin Haustermans,et al.  Value of diffusion-weighted magnetic resonance imaging for prediction and early assessment of response to neoadjuvant radiochemotherapy in rectal cancer: preliminary results. , 2012, International journal of radiation oncology, biology, physics.

[41]  Stef van Buuren,et al.  MICE: Multivariate Imputation by Chained Equations in R , 2011 .

[42]  V. Gebski,et al.  Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. , 2011, The Lancet. Oncology.

[43]  H. Matsubara,et al.  Apparent Diffusion Coefficient Values Measured by Diffusion-Weighted Imaging Predict Chemoradiotherapeutic Effect for Advanced Esophageal Cancer , 2011, Digestive Surgery.

[44]  Brian D Ross,et al.  Predicting and monitoring cancer treatment response with diffusion‐weighted MRI , 2010, Journal of magnetic resonance imaging : JMRI.

[45]  Trevor Hastie,et al.  Regularization Paths for Generalized Linear Models via Coordinate Descent. , 2010, Journal of statistical software.

[46]  V. Harry.  Novel imaging techniques as response biomarkers in cervical cancer. , 2010, Gynecologic oncology.

[47]  Uulke A. van der Heide,et al.  Simultaneous multi-modality ROI delineation in clinical practice , 2009, Comput. Methods Programs Biomed..

[48]  P. Choyke,et al.  Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. , 2009, Neoplasia.

[49]  Leslie H. Sobin,et al.  Comprar TNM Classification of Malignant Tumours, 7th Edition | C. Wittekind | 9781444332414 | Wiley , 2009 .

[50]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[51]  T. Djärv,et al.  Long‐term health‐related quality of life following surgery for oesophageal cancer , 2008, The British journal of surgery.

[52]  Guido Gerig,et al.  User-guided 3D active contour segmentation of anatomical structures: Significantly improved efficiency and reliability , 2006, NeuroImage.

[53]  V. Gebski,et al.  Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. , 2005, The Lancet. Oncology.

[54]  T. Perneger.  What's wrong with Bonferroni adjustments , 1998, BMJ.

[55]  T. Walsh,et al.  A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. , 1996, The New England journal of medicine.

[56]  J. Petiot,et al.  Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations , 1994, Cancer.

[57]  A. Cassoni.  Tnm Classification of Malignant Tumours , 1987 .